

# Directorate Change

RNS Number : 3166K

Novacyt S.A.

31 October 2024

NOVACYT

**Novacyt S.A.**

**("Novacyt", the "Company" or the "Group")**

## **Directorate Change**

Dr Ian Gilham appointed as Non-Executive Director

**Paris, France, Eastleigh and Manchester, UK - 31 October 2024** - Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces the appointment of Dr Ian Gilham as a Non-Executive Director with immediate effect. Dr Gilham will become a Board Director of the Company, subject to shareholder approval, at the Company's Annual General Meeting.

Ian has a wealth of experience in AIM-listed life sciences companies, with an international track record in the research, development and commercialisation of diagnostic products that will further strengthen the expertise of the Novacyt Board. He currently holds roles as Non-Executive Chairman of AIM-listed Genedrive PLC, Chair of Trustees for LifeArc, a self-funded medical research charity, Non-Executive Chairman of Pelago Bioscience AB, a life sciences tools business based in Stockholm and Non-Executive Chairman of RevoNA Bio, a University of Portsmouth spinout life sciences tools company. Ian has previously held Board positions at Aptamer Group PLC, Horizon Discovery PLC, Cytos Ltd, Elucigene Ltd, Multiplicom n.v, Biosufit s.a, Vernalis plc, Concepta Diagnostics Ltd and was CEO of Axis-Shield PLC.



**Dr Ian Gilham, Non-Executive Director of Novacyt S.A.**

**Lyn Rees, CEO of Novacyt, commented:** "It is a pleasure to welcome Ian to the Board of Novacyt. Ian has worked with a number of successful AIM-listed life sciences companies and we look forward to utilising his expertise as we further optimise and strengthen the Novacyt Group."

### Additional Information

The following information is disclosed pursuant to Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies in relation to Ian David Gilham aged 64.

Current Directorships / Partnerships	Former Directorships / Partnerships within the last 5 years
Genedrive Plc LifeArc Pelago Bioscience AB Revona Bio Ltd Stowheath Limited	Aptamer Group Plc BIOSURFIT s.a Cytex Limited Horizon Discovery Group Limited (Formerly Horizon Discovery Plc) Revvity Discovery Limited (Formerly Horizon Discovery Limited)

On 4 January 2024, Cytex Limited, a company which Ian Gilham was previously a director of, appointed a liquidator in connection with a creditors voluntary winding up. No notice of administrators' proposal has yet been filed although the business was estimated to have a deficiency as regards creditors of £257,405.

Save as disclosed above, there is no further information to be disclosed in respect of the above appointment pursuant to Rule 17 and Schedule 2 paragraph (g) of the AIM Rules for Companies.

### Contacts

<b>Novacyt SA</b>	<a href="https://novacyt.com/investors">https://novacyt.com/investors</a>
Lyn Rees, Chief Executive Officer	<b>Via Walbrook PR</b>
Steve Gibson, Chief Financial Officer	
<b>SP Angel Corporate Finance LLP (Nominated Adviser and Broker)</b>	<b>+44 (0)20 3470 0470</b>
Matthew Johnson / Charlie Bouverat (Corporate Finance) Vadim Alexandre / Rob Rees (Corporate Broking)	

Deutsche Numis (Joint Broker)

+44 (0)20 7260 1000

Freddie Barnfield / Duncan Monteith / Michael Palser

Allegra Finance (French Listing Sponsor)  
Rémi Durgetto / Yannick Petit

+33 (1) 42 22 10 10 r.durgetto@allegrafinance.com /  
y.petit@allegrafinance.com

Walbrook PR (Financial PR & IR)  
Paul McManus / Lianne Applegarth  
Phillip Marriage / Alice Woodings

+44 (0)20 7933 8780 or novacyt@walbrookpr.com  
+44 (0)7980 541 893 / +44 (0)7584 391 303  
+44 (0)7867 984 082 / +44 (0)7407 804 654

### About Novacyt Group ([www.novacyt.com](http://www.novacyt.com))

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

#### Clinical

Broad portfolio of human clinical *in vitro* diagnostic products, workflows and services focused on three therapeutic areas:

- Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests
- Precision Medicine: DPYD genotyping assay
- Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel

#### Instrumentation

Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:

- Ranger® Technology: automated DNA sample preparation and target enrichment technology
- genesig q16 and q32 real-time quantitative PCR (qPCR) instruments

#### Research Use Only

Range of services for the life sciences industry:

- Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry
- Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)

Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the UK (in Eastleigh and Manchester), Singapore, the US and Canada and has a commercial presence in over 65 countries. The Company is listed on the London Stock Exchange's AIM market ("NCYT") and on the Paris Stock Exchange Euronext Growth ("ALNOV").

For more information, please refer to the website: [www.novacyt.com](http://www.novacyt.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com). RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAMMBBTMTJJTJI